Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits
News Aug 01, 2012
Bio-Rad Laboratories, Inc. and Myriad RBM, Inc. have announced that they have partnered to develop and distribute high-quality immunoassay kits.
Under the terms of the agreement, Myriad RBM grants Bio-Rad exclusive distribution rights, for research purposes, to the largest catalog of quantitative multiplexed immunoassays currently available to run on the Bio-Plex® 200, Bio-Plex® 3D, and Bio-Plex® MAGPIX™ instruments.
Myriad RBM's assays address researchers' needs for multiplex testing of samples with very low volumes when studying toxicology, oncology, immunology, and cardiovascular and other diseases. The new assays expand Bio-Rad's current suite of assays.
"Together we are able to provide hundreds of new biomarkers for both human and non-human panels to our Bio-Plex multiplex immunoassay system menu," said Brad Crutchfield, Bio-Rad Vice President and Group Manager, Life Science Group.
Crutchfield continued, "Moving forward, Myriad RBM and Bio-Rad will collaborate to design new products to meet the evolving requirements of our customers."
"This agreement combines Myriad RBM's industry-leading menu of multiplexed immunoassays with Bio-Rad's unrivaled global commercial distribution capabilities," said Craig Benson, President of Myriad RBM.
Benson continued, "Our partnership with Bio-Rad will help researchers and clinicians on the front lines of medicine to develop biomarker profiles that may predict, detect, or monitor disease progression in an effort to optimize treatment and improve patient care."
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE